X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used in the development and commercialization of Zoryve (roflumilast), which is a phosphodiesterase 4 inhibitor. It is being evaluated in clinical trial studies for the treatment of Atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Details:
The net proceeds will be used in the development and commercialization of Zoryve (roflumilast), which is a phosphodiesterase 4 inhibitor. It is being evaluated in clinical trial studies for the treatment of Atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2024
Details:
The collaboration aims to enable Sato to concentrate on the development, manufacturing, and commercialization of topical Zoryve (roflumilast) in Japan. It is used in the treatment of Plaque Psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sato Yakuhin Kogyo Co., Ltd
Deal Size: $40.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration February 28, 2024
Details:
Zoryve (roflumilast) is a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. Its topical foam (0.3%) is approved for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Zoryve (roflumilast) is a once-daily, PDE4 inhibitor steroid-free cream which is being investigated in phase 3 clinical trials for adults and children 6 years of age and older with atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2024
Details:
Zoryve (roflumilast) is a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. Its topical foam (0.3%) is approved for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
Zoryve (roflumilast) topical foam, 0.3%, is indicated for treatment of seborrheic dermatitis in adult & pediatric patients 9 years of age & older. Zoryve, roflumilast cream 0.3%, is approved by FDA for the treatment of plaque psoriasis in individuals 6 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
Zoryve (roflumilast) is a PDE4 Inhibitor small molecule drug, formulated as a topical cream for the treatment of Atopic Dermatitis in Adults and Children Down to Age 6.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
Zoryve® (roflumilast cream) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor, which is used for topical treatment of Psoriasis in Children Ages 6 to 11.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Arcutis intends to use the net proceeds to fund the continued development, approval and commercialization of its multiple programs, including for its potential launches in seborrheic dermatitis and atopic dermatitis and further patient expansion within psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
